Research programme: anti-PD-L1/TGF-beta bispecific antibodies - GigaGen
Alternative Names: Anti-PD-L1 x anti-TGF-ß bispecific antibodies- GigaGenLatest Information Update: 28 May 2021
At a glance
- Originator GigaGen
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants; Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer